Recent controversy over the cost of Sovaldi (Gilead Sciences)-a $1000-per-dose treatment for hepatitis C-has sparked a debate as to whether there should be federal caps on the costs of certain prescription drugs.
Recent controversy over the cost of Sovaldi (Gilead Sciences)—a $1000-per-dose treatment for hepatitis C—has sparked a debate as to whether there should be federal caps on the costs of certain prescription drugs. Rising costs for specialty medications such as Sovaldi keeps certain patients from receiving life-saving treatments.
“The Sovaldi example has brought us to a crossroads,” said Karen Ignagni, president and CEO of America's Health Insurance Plans. “We need to sit together to begin talking about how we can attack this problem together before the government has to. We cannot sustain 6-figure therapies and we're at the beginning of that trend.”
Insurers and public health officials alike have voiced concern over not only the financial burden of drugs like Solvaldi, but the moral and ethical issues that arise when deciding which patients are entitled to have it. As well, Medicare and Medicaid programs are likely going to feel additional financial strain as the baby boomer generation becomes eligible for benefits.
“Manufacturers are charging whatever they can get away with,” Ms Ignagni said. “We can’t have a system that operates that way. We can’t sustain it. It will go back to blowing up family budgets and blowing up Part D and blowing up the federal government … it’s a vicious circle here.”
Many drug manufacturers maintain that developing innovative drugs is costly and can take years. John Castellani, president and CEO of Pharmaceutical Research and Manufacturers of America, said that the average prescription medication costs $1.2 billion to develop, and can take 10 to 12 years before it gets through FDA approvals for market distribution.
Sara Radcliffe, executive vice president for health at the Biotechnology Industry Organization, said that drugs like Sovaldi can actually reduce costs by eliminating the need for more costly procedures down the road. It may be harder to convince others that the pricing is justified.
“It’s a huge discussion in our industry,” Ms Radcliffe said. “How do we create the products that those on the reimbursement side are going to pay for?”
Ms Ignagni suggested that further discussions over the future of innovative pharmaceuticals will be needed among stakeholders.
Around the Web
Excessive Drug Costs Could Invite Price Caps: AHIP's Ignagni [Modern Healthcare]
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More